Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin’s Lymphoma
Study Information
Alliance Study ID: NCCTG-947851
NCT Study ID (ClinicalTrials.gov): NCT00002779
Alliance Committee: Lymphoma
Disease or Cancer Type: Lymphoma
Alliance Study Chair: Thomas E. Witzig, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of fludarabine plus octreotide in treating patients who have relapsed low-grade non-Hodgkin’s lymphoma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information